{
    "id": 13382,
    "fullName": "ABL1 M244V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 M244V lies within the protein kinase domain of the Abl1 protein (UniProt.org). M244V has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL1 (PMID: 21562040), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "M244V",
    "createDate": "10/29/2015",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119199,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130862943A>G",
        "cDna": "c.730A>G",
        "protein": "p.M244V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11926,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 M244V was associated with resistance to Gleevec (imatinib) in patients with BCR-ABL1-positive chronic myeloid leukemia (PMID: 17189410).",
            "molecularProfile": {
                "id": 22839,
                "profileName": "BCR - ABL1 ABL1 M244V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9909,
                    "pubMedId": 17189410,
                    "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17189410"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6252,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 56% (4/9) of chronic myeloid leukemia patients harboring ABL1 M244V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22839,
                "profileName": "BCR - ABL1 ABL1 M244V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7995,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359V (91%), and F359V/M244V (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 22973,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6379,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) resulted in a major molecular response in a patient with heavily pretreated chronic myeloid leukemia expressing BCR-ABL1, ABL1 M244V, and ABL1 G250W in a minority of BCR-ABL1 positive clones (PMID: 26603839).",
            "molecularProfile": {
                "id": 23172,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7994,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 M244V (89%), F359V (3%), and M244V/G250W (2%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26131,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Gleevec (imatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated sensitivity to Rebastinib (DCC-2036) in culture, resulting in decreased cell proliferation (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Bosulif (bosutinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18860,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated sensitivity to Iclusig (ponatinib) in culture, resulting in decreased cell proliferation (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20986,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 M244V and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35475,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20987,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 M244V and E459K in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35476,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13568,
            "profileName": "ABL1 M244V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22839,
            "profileName": "BCR - ABL1 ABL1 M244V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22973,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23172,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26131,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33624,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35475,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35476,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119199,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130862943A>G",
            "cDna": "c.730A>G",
            "protein": "p.M244V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}